Search

everythinglearnresearchcommunity

for

Search:↓

Certain groups of medications given when leaving the hospital are linked to a higher risk of negative drug reactions within 30 days, especially in older adults with respiratory issues.

More people in South Korea are using statins each year, especially those with diabetes, muscle pain, and heart disease, leading to higher medical costs.

Women are more likely to have long-term post-COVID symptoms than men.

Many COVID-19 survivors continue to experience symptoms like fatigue and concentration problems after recovery, possibly needing rehabilitation.

Tinea capitis, a scalp fungal infection in children, is best treated with newer antifungal agents for shorter periods.

COVID-19 infection can significantly cause temporary hair loss.

Stem cell therapy shows promise in improving burn wound healing.

Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.

COVID-19 vaccines are safe and highly effective for children, with inactivated vaccines being slightly better.

Gendered social factors, not just biology, contribute to sex differences in adverse drug events.

Many COVID-19 patients experience temporary hair loss after infection, not linked to infection severity or treatment.

COVID-19 can cause hair loss starting as early as 18 days after infection.

COVID-19 can cause temporary hair loss, often starting around 7-8 weeks after recovery, with factors like Vitamin D deficiency, other diseases, medication, and stress potentially contributing.

Quercetin may help improve symptoms of polycystic ovary syndrome.

Early treatment improved COVID-19 outcomes, and spironolactone helped reduce risks in females with high androgen levels.

Certain bacteria from the Citrullus colocynthis plant may be a new source of antibiotics to fight drug-resistant diseases.

Injecting scalp tissue micrografts is a safe and effective treatment for hair loss after COVID-19.

Monocytes might be linked to hair loss after COVID-19.

Oral retinoic acid effectively treated collodion baby, with hair loss as the main side effect.

The 2012 criteria are better for diagnosing atypical lupus cases.

Androgenetic alopecia severity does not affect COVID-19 severity.

Oxygenated micro/nanobubbles speed up burn wound healing in rats.

Biofibre hair implants are safe, well-tolerated, and provide immediate cosmetic improvement for hair loss.

Stopping birth control pills may have triggered a manic episode in a woman with HAIR-AN syndrome.

Chitosan scaffolds with silver nanoparticles effectively treat infected wounds and promote faster healing.

High-dose vitamin D3 does not improve symptoms or quality of life in COVID-19 patients after one year.

A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.

Skin emergency severity rises with other health issues and affects multiple organs; a new grading system can improve patient care.

Chronic arsenic exposure can cause liver damage and other health issues.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.